Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Ocrelizumab (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Biomarker; Therapeutic Use
- Sponsors Genentech; Roche
- 17 Feb 2024 Status changed from active, no longer recruiting to completed.
- 01 Feb 2024 Results of exploratory analyses from longest follow-up to date of ocrelizumab-treated patients with relapsing-remitting MS (RRMS), published in the Journal of Neurology
- 03 Jan 2024 Planned End Date changed from 16 Dec 2023 to 16 Jan 2024.